Compare BridgeBio Pharma Inc (BBIO) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Warner Music Group Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Warner Music Group Corp trades at $25.2 (market cap $13.82B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and Warner Music Group Corp pays a 3.03% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | WMG | |
|---|---|---|
Market Cap | $16.61B | $13.82B |
Sector | Health | Media |
52-Week High | $90.17 | $34.72 |
52-Week Low | $47.29 | $23.65 |
Enterprise Value | $18.16B | $18.12B |
Dividend Yield | — | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Warner Music Group (WMG) trades at $26.39, showing modest daily movement with a slight 0.19% decline. The stock exhibits bearish technical signals despite recent earnings beats in Q1 and Q2 2026. Fundamentally, revenue has grown consistently from $5.9B in 2022 to $6.7B in 2025, though net income margin declined to 5.44%. The company maintains strong profitability metrics with 45.77% gross margin and 25.38% ROE, while analyst sentiment remains positive with 66.7% buy ratings.
WMG presents a compelling value opportunity with reasonable valuation multiples (P/E 21.11, P/S 1.89) and strong analyst support. Near-term catalysts include streaming revenue growth and new licensing partnerships, though risks include margin pressure and leadership transitions. The stock's current technical weakness may offer entry points for long-term investors seeking exposure to music industry consolidation and digital transformation trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
